Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial.

MLA

Geoerger, Birgit, et al. “Afatinib in Paediatric Patients with Recurrent/Refractory ErbB-Dysregulated Tumours: Results of a Phase I/Expansion Trial.” European Journal of Cancer (Oxford, England : 1990), vol. 188, July 2023, pp. 8–19. EBSCOhost, https://doi.org/10.1016/j.ejca.2023.04.007.

APA

Geoerger, B., Marshall, L. V., Nysom, K., Makin, G., Bouffet, E., Defachelles, A.-S., Amoroso, L., Aerts, I., Leblond, P., Barahona, P., Van-Vlerken, K., Fu, E., Solca, F., Lorence, R. M., & Ziegler, D. S. (2023). Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. European Journal of Cancer (Oxford, England : 1990), 188, 8–19. https://doi.org/10.1016/j.ejca.2023.04.007

Chicago

Geoerger, Birgit, Lynley V Marshall, Karsten Nysom, Guy Makin, Eric Bouffet, Anne-Sophie Defachelles, Loredana Amoroso, et al. 2023. “Afatinib in Paediatric Patients with Recurrent/Refractory ErbB-Dysregulated Tumours: Results of a Phase I/Expansion Trial.” European Journal of Cancer (Oxford, England : 1990) 188 (July): 8–19. doi:10.1016/j.ejca.2023.04.007.